drugset / Trial / NCT01189760

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

NCT01189760 ↗

Phase 3 Completed 917 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides)

Timeline

Start
2010-09-01
Primary completion
2011-03-01
Completion
2011-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 24 iu —
Subject Botulinum toxin type A Protein / enzyme biologic 44 iu —

Indications

No indication recorded.